Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pharmos, Bausch & Lomb Pharmaceuticals Inc. deal

PARS finalized its previously announced agreement with Bausch & Lomb to market Lotemax, a site-specific ocular steroidal anti-inflammatory

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE